CTMC / A joint venture between Resilience + MD Anderson Cancer Center
Cathy Xueqian Wang has extensive experience in the field of viral vector and cell line development for cell therapy and gene therapy applications. Cathy Xueqian has held positions at various prestigious organizations, leading teams and being involved in the development and optimization of viral vectors, as well as analytical assays for cell products. Cathy Xueqian has a solid educational background with a Ph.D. in Biology and a Bachelor's degree in Biochemistry. Throughout their career, Cathy Xueqian has contributed significantly to the advancement of technology in the field of genetic engineering and cell therapy.
This person is not in any offices
CTMC / A joint venture between Resilience + MD Anderson Cancer Center
Cell Therapy Manufacturing Center (CTMC) is a joint venture between Resilience and MD Anderson Cancer Center. CTMC was created to bring together the leading complex biologics manufacturing technology organization and the #1 clinical cancer center to enable innovation from academia and biotech to accelerate Cell Therapy’s impact for cancer patients.
Employees
51-200